Showing results (171-180 of 214) with videos related to
Sort By:
Pageof 22
Microbial Biotechnology|November 6, 2022
The host niches of soybean rather than genetic modification or glyphosate application drive the assembly of root-associated microbial communitiesMinkai Yang, Fuhe Luo, Yuchen Song, et al.Journal of Thoracic Disease|January 7, 2020
A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancerKan Wu, Lucheng Zhu, Jiahao Wang, et al.Japanese Journal of Clinical Oncology|April 10, 2015
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST studyYisheng Huang, Li Zhang, Yuankai Shi, et al.Journal of Thoracic Disease|September 4, 2018
ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world settingShirong Zhang, Lucheng Zhu, Xueqin Chen, et al.Oncotarget|September 17, 2016
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cellsShirong Zhang, Kan Wu, Jianguo Feng, et al.Journal of Thoracic Disease|January 12, 2026
Development of a machine learning-based model to predict prognosis of resected invasive pulmonary adenocarcinomaJie Huang, Jiannan Qian, Yunshan Zhong, et al.Cell Research|April 17, 2020
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamidePeihua Luo, Hao Yan, Xueqin Chen, et al.The European Respiratory Journal|June 27, 2015
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II studyHilary J Goldberg, Sergio Harari, Vincent Cottin, et al.Cancers|July 9, 2022
Dysregulated Immune and Metabolic Microenvironment Is Associated with the Post-Operative Relapse in Stage I Non-Small Cell Lung CancerShirong Zhang, Xiao Xiao, Xiuli Zhu, et al.Cellular & Molecular Immunology|June 12, 2020
Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathwayBo Huang, Yufeng Qian, Shujun Xie, et al.Pageof 22